Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
| ▸ | CA7 | P43166 | 1/20 | 0.45 |
| ▸ | SYK | P43405 | 1/20 | 0.44 |
| ▸ | CTSK | P43235 | 8/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | CTSS | P25774 | 4/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | AAK1 | Q2M2I8 | 3/20 | 0.38 |
| ▸ | CTSL | P07711 | 1/20 | 0.37 |
| ▸ | CTSB | P07858 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1987512 | 1.00 | CA1 (0.45) | CA1CA2CA7SYKCTSK | |
| SCHEMBL1987513 | 1.00 | CA1 (0.45) | CA1CA2CA7SYKCTSK | |
| SCHEMBL3389057 | 0.91 | CA1 (0.49) | CA1CA2CA7SYKCTSK | |
| SCHEMBL31754649 | 0.88 | CA1 (0.41) | CA1CA2CA7SYKCTSK | |
| SCHEMBL7498266 | 0.87 | CA1 (0.41) | CA1CA2CA7SYKCTSK | |
| SCHEMBL2861782 | 0.87 | CA1 (0.52) | CA1CA2CA7CTSKCYP2D6 | |
| SCHEMBL24963220 | 0.86 | CA1 (0.42) | CA1CA2CA7SYKCTSK | |
| SCHEMBL5221835 | 0.86 | CA1 (0.42) | CA1CA2CA7SYKCTSK | |
| SCHEMBL28634143 | 0.86 | CA1 (0.42) | CA1CA2CA7SYKCTSK | |
| SCHEMBL5822289 | 0.86 | CA1 (0.42) | CA1CA2CA7SYKCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4396191-B1 | COMPOUNDS USEFUL IN MODULATION OF AHR SIGNALLING | JAGUAHR THERAPEUTICS PTE LTD (SG) | 2026-02-18 | — | — | EP | disclosed |
| US-20250129092-A1 | COMPOUNDS USEFUL IN MODULATION OF AHR SIGNALLING | JAGUAHR THERAPEUTICS PTE LTD (SG) | 2025-04-24 | — | — | US | disclosed |
| US-20250026721-A1 | COMPOUNDS AND METHODS FOR MODULATING RAS-PI3K | VIVIDION THERAPEUTICS, INC. | 2025-01-23 | — | — | US | disclosed |
| CN-115594680-A | TEAD inhibitor | 武汉人福创新药物研发中心有限公司（CN） | 2023-01-13 | — | — | CN | disclosed |
| WO-2023280254-A1 | TEAD INHIBITOR | 武汉人福创新药物研发中心有限公司 | 2023-01-12 | — | — | WO | disclosed |
| EP-2540720-B1 | 1,3,4,8-TETRAHYDRO-2H-PYRIDO[1,2-A]PYRAZINE DERIVATIVE AND USE OF SAME AS HIV INTEGRASE INHIBITOR | JAPAN TOBACCO INC (JP) | 2015-04-15 | — | — | EP | disclosed |
| US-8748660-B2 | Process for the synthesis of antiepileptic drug lacosamide | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2014-06-10 | — | — | US | disclosed |
| US-8748660-B2 | Process for the synthesis of antiepileptic drug lacosamide | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2014-06-10 | — | — | US | disclosed |
| US-8748660-B2 | Process for the synthesis of antiepileptic drug lacosamide | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2014-06-10 | — | — | US | disclosed |
| US-20140012044-A1 | PROCESS FOR THE SYNTHESIS OF ANTIEPILEPTIC DRUG LACOSAMIDE | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2014-01-09 | — | — | US | disclosed |
| US-20140012044-A1 | PROCESS FOR THE SYNTHESIS OF ANTIEPILEPTIC DRUG LACOSAMIDE | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2014-01-09 | — | — | US | disclosed |
| US-20140012044-A1 | PROCESS FOR THE SYNTHESIS OF ANTIEPILEPTIC DRUG LACOSAMIDE | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2014-01-09 | — | — | US | disclosed |
| US-20070129371-A1 | Novel ethylenediamine derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-06-07 | — | — | US | disclosed |
| US-20070129371-A1 | Novel ethylenediamine derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-06-07 | — | — | US | disclosed |
| US-20050288376-A1 | Bicyclyl or heterobicyclylmethanesulfonylanimo-substituted N-hydroxyformamides | SMITHKLINE BEECHAM PLC | 2005-12-29 | — | — | US | disclosed |
| EP-1289980-B1 | BICYCLYL OR HETEROBICYCLYLMETHANESULFONYLAMINO-SUBSTITUTED N-HYDROXYFORMAMIDES | SMITHKLINE BEECHAM PLC (GB) | 2004-11-17 | — | — | EP | disclosed |
| US-20040024066-A1 | Bicyclyl or heterobicyclylmethanesulfonylamino-substituted n-hydroxyformamides | SMITHKLINE BEECHAM P.L.C. (GB) | 2004-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070129371-A1 | Novel ethylenediamine derivatives | C1R, C9, C1S | CA1 1918/4885CA2 3666/4885CA7 3754/4885 |
| US-20250129092-A1 | COMPOUNDS USEFUL IN MODULATION OF AHR SIGNALLING | AHR, ARNT, AIPL1 | CA1 4814/4885CA2 4345/4885CA7 4640/4885 |
| US-20250026721-A1 | COMPOUNDS AND METHODS FOR MODULATING RAS-PI3K | KRAS, HRAS, NRAS | CA1 4347/4885CA2 3649/4885CA7 3489/4885 |
| US-20140012044-A1 | PROCESS FOR THE SYNTHESIS OF ANTIEPILEPTIC DRUG LACOSAMIDE | GNE, GABRE, GALE | CA1 159/4885CA2 107/4885CA7 458/4885 |
| US-20050288376-A1 | Bicyclyl or heterobicyclylmethanesulfonylanimo-substituted N-hydroxyformamides | CD22, CD2, NEU3 | CA1 1017/4885CA2 1247/4885CA7 2273/4885 |
| US-20040024066-A1 | Bicyclyl or heterobicyclylmethanesulfonylamino-substituted n-hydroxyformamides | CD22, CD2, NEU3 | CA1 659/4885CA2 1162/4885CA7 1898/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.